Expanded AAV capacity Virovek specializes in customized and large-scale AAV production with a platform capable of producing high-titer vectors and accommodating any serotype, offering a compelling target for partners requiring scalable gene delivery vectors.

Academic to industry reach With thousands of AAV vectors produced for over 100 universities, non-profits, and industry leaders, Virovek demonstrates a broad, proven track record and potential for collaboration across research-intensive accounts seeking reliable AAV support.

Licensing opportunities Proprietary BAC-to-AAV and toxin-based cell ablation technologies are available for non-exclusive licensing, presenting a potential revenue stream through tech transfer deals or strategic collaborations.

Strategic leadership change Recent CEO appointment signals leadership maturity and potential strategic shifts to scale commercialization, partnerships, and service offerings, which can be leveraged in outreach to prospective customers and channel partners.

Global expansion potential Active interest in partnerships beyond current regions, including Africa and Oceania, indicates growth opportunities for international collaboration, regional service expansion, and localized sales initiatives.